Aberdeen Group
IMVT icon

Aberdeen Group’s Immunovant IMVT Stock Holding History

Aberdeen Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33M Sell
857,030
-303,732
-26% -$9.25M 0.05% 311
2026
Q1 		$28.8M Sell
1,160,762
-23,360
-2% -$605K 0.05% 314
2025
Q4 		$30.1M Buy
1,184,122
+202,318
+21% +$4.51M 0.05% 318
2025
Q3 		$15.8M Buy
981,804
+137,099
+16% +$2.22M 0.03% 509
2025
Q2 		$13.5M Buy
844,705
+25,228
+3% +$381K 0.02% 528
2025
Q1 		$14M Buy
819,477
+287,367
+54% +$6.01M 0.03% 479
2024
Q4 		$13.2M Buy
532,110
+53,353
+11% +$1.51M 0.02% 456
2024
Q3 		$13.6M Buy
478,757
+78,035
+19% +$2.3M 0.03% 459
2024
Q2 		$10.6M Buy
400,722
+213,086
+114% +$6.06M 0.02% 502
2024
Q1 		$6.06M Sell
187,636
-140,070
-43% -$5.11M 0.01% 637
2023
Q4 		$13.8M Buy
+327,706
New +$12.1M 0.03% 483

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Aberdeen Group's IMVT Position: Q2 2026 in Review

Aberdeen Group reduced its Immunovant (IMVT) stake by 26% in Q2 2026, selling an estimated $9.25M and leaving 857,030 shares worth $33M. The position accounts for 0.05% of the portfolio, ranked #311.

Aberdeen Group first reported a position in IMVT in Q4 2023 and has held it in 11 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Aberdeen Group held 857,030 shares of Immunovant worth $33M as of Q2 2026.
  • Aberdeen Group sold 303,732 Immunovant shares in Q2 2026, an estimated $9.25M.
  • Immunovant made up 0.05% of Aberdeen Group's portfolio in Q2 2026, its #311 holding.
  • Aberdeen Group first reported a position in Immunovant in Q4 2023 and has held it in 11 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.